Skip to main content
Top
Published in: European Journal of Nutrition 8/2018

01-12-2018 | Short Communication

Dietary guanidinoacetic acid does not accumulate in the brain of healthy men

Authors: Sergej M. Ostojic, Jelena Ostojic

Published in: European Journal of Nutrition | Issue 8/2018

Login to get access

Abstract

We conducted a secondary analysis of a previously completed trial to determine the effects of 8-week guanidinoacetic acid (GAA) loading on brain GAA levels in five healthy men. Brain magnetic resonance spectroscopy (1H-MRS) was taken at baseline and post-administration, with spectra additionally analyzed for brain GAA and glutamate concentrations using TARQUIN 4.3.10 software. Brain GAA levels remained essentially unchanged at follow-up (an increase of 7.7% from baseline levels; 95% confidence interval, - 24.1% to 39.5%; P = 0.88) when averaged across 12 white and grey matter voxel locations. No significant changes were found for brain glutamate levels during the study (P = 0.64). Supplemental GAA appears to be safe intervention concerning brain GAA deposition, at least with GAA dosages used.
Literature
1.
go back to reference Ostojic SM, Stojanovic MD, Hoffman JR (2015) Six-week oral guanidinoacetic acid administration improves muscular performance in healthy volunteers. J Investig Med 63:942–946PubMed Ostojic SM, Stojanovic MD, Hoffman JR (2015) Six-week oral guanidinoacetic acid administration improves muscular performance in healthy volunteers. J Investig Med 63:942–946PubMed
2.
go back to reference Ostojic SM, Stojanovic M, Drid P, Hoffman JR, Sekulic D, Zenic N (2016) Supplementation with guanidinoacetic acid in women with chronic fatigue syndrome. Nutrients 8:72CrossRef Ostojic SM, Stojanovic M, Drid P, Hoffman JR, Sekulic D, Zenic N (2016) Supplementation with guanidinoacetic acid in women with chronic fatigue syndrome. Nutrients 8:72CrossRef
3.
go back to reference Ostojic SM, Ostojic J, Drid P, Vranes M, Jovanov P (2017) Dietary guanidinoacetic acid increases brain creatine levels in healthy men. Nutrition 33:149–156CrossRef Ostojic SM, Ostojic J, Drid P, Vranes M, Jovanov P (2017) Dietary guanidinoacetic acid increases brain creatine levels in healthy men. Nutrition 33:149–156CrossRef
4.
go back to reference Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, Appleton R, Araújo HC, Duran M, Ensenauer R, Fernandez-Alvarez E, Garcia P, Grolik C, Item CB, Leuzzi V, Marquardt I, Mühl A, Saelke-Kellermann RA, Salomons GS, Schulze A, Surtees R, van der Knaap MS, Vasconcelos R, Verhoeven NM, Vilarinho L, Wilichowski E, Jakobs C (2006) GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 67:480–484CrossRef Mercimek-Mahmutoglu S, Stoeckler-Ipsiroglu S, Adami A, Appleton R, Araújo HC, Duran M, Ensenauer R, Fernandez-Alvarez E, Garcia P, Grolik C, Item CB, Leuzzi V, Marquardt I, Mühl A, Saelke-Kellermann RA, Salomons GS, Schulze A, Surtees R, van der Knaap MS, Vasconcelos R, Verhoeven NM, Vilarinho L, Wilichowski E, Jakobs C (2006) GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 67:480–484CrossRef
5.
go back to reference Liversedge LA (1956) Glycocyamine and betaine in motor-neurone disease. Lancet 271:1136–1138CrossRef Liversedge LA (1956) Glycocyamine and betaine in motor-neurone disease. Lancet 271:1136–1138CrossRef
6.
go back to reference Tsubakihara Y, Suzuki A, Hayashi T, Shoji T, Togawa M, Okada N (1999) The effect of guanidinoacetic acid supplementation in patients with chronic renal failure. In: Mori A, Ishida M, Clark JF (eds) Guanidino compounds in biology and medicine vol 5. Blackwell, Tokyo, pp 139–144 Tsubakihara Y, Suzuki A, Hayashi T, Shoji T, Togawa M, Okada N (1999) The effect of guanidinoacetic acid supplementation in patients with chronic renal failure. In: Mori A, Ishida M, Clark JF (eds) Guanidino compounds in biology and medicine vol 5. Blackwell, Tokyo, pp 139–144
7.
go back to reference Ostojic SM, Niess B, Stojanovic M, Obrenovic M (2013) Creatine metabolism and safety profiles after six-week oral guanidinoacetic acid administration in healthy humans. Int J Med Sci 10:141–147CrossRef Ostojic SM, Niess B, Stojanovic M, Obrenovic M (2013) Creatine metabolism and safety profiles after six-week oral guanidinoacetic acid administration in healthy humans. Int J Med Sci 10:141–147CrossRef
8.
go back to reference European Food Safety Authority (2009) Safety and efficacy of guanidinoacetic acid as feed additive for chickens for fattening. EFSA J 988:1–30 European Food Safety Authority (2009) Safety and efficacy of guanidinoacetic acid as feed additive for chickens for fattening. EFSA J 988:1–30
9.
go back to reference Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC (2011) A constrained least-squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data. Magn Reson Med 65:1–12CrossRef Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC (2011) A constrained least-squares approach to the automated quantitation of in vivo 1H magnetic resonance spectroscopy data. Magn Reson Med 65:1–12CrossRef
10.
go back to reference Clark JF, Cecil KM (2015) Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes. Pediatr Res 77:398–405CrossRef Clark JF, Cecil KM (2015) Diagnostic methods and recommendations for the cerebral creatine deficiency syndromes. Pediatr Res 77:398–405CrossRef
11.
go back to reference Bianchi MC, Tosetti M, Battini R, Leuzzi V, Alessandri’ MG, Carducci C, Antonozzi I, Cioni G (2007) Treatment monitoring of brain creatine deficiency syndromes: a 1H- and 31P-MR spectroscopy study. AJNR Am J Neuroradiol 28:548–554PubMed Bianchi MC, Tosetti M, Battini R, Leuzzi V, Alessandri’ MG, Carducci C, Antonozzi I, Cioni G (2007) Treatment monitoring of brain creatine deficiency syndromes: a 1H- and 31P-MR spectroscopy study. AJNR Am J Neuroradiol 28:548–554PubMed
12.
go back to reference Verbruggen KT, Sijens PE, Schulze A, Lunsing RJ, Jakobs C, Salomons GS, van Spronsen FJ (2007) Successful treatment of a guanidinoacetate methyltransferase deficient patient: findings with relevance to treatment strategy and pathophysiology. Mol Genet Metab 91:294–296CrossRef Verbruggen KT, Sijens PE, Schulze A, Lunsing RJ, Jakobs C, Salomons GS, van Spronsen FJ (2007) Successful treatment of a guanidinoacetate methyltransferase deficient patient: findings with relevance to treatment strategy and pathophysiology. Mol Genet Metab 91:294–296CrossRef
13.
go back to reference Ostojic SM, Ostojic J, Drid P, Vranes M (2016) Guanidinoacetic acid versus creatine for improved brain and muscle creatine levels: a superiority pilot trial in healthy men. Appl Physiol Nutr Metab 41:1005–1007CrossRef Ostojic SM, Ostojic J, Drid P, Vranes M (2016) Guanidinoacetic acid versus creatine for improved brain and muscle creatine levels: a superiority pilot trial in healthy men. Appl Physiol Nutr Metab 41:1005–1007CrossRef
14.
go back to reference Neu A, Neuhoff H, Trube G, Fehr S, Ullrich K, Roeper J, Isbrandt D (2002) Activation of GABA(A) receptors by guanidinoacetate: a novel pathophysiological mechanism. Neurobiol Dis 11:298–307CrossRef Neu A, Neuhoff H, Trube G, Fehr S, Ullrich K, Roeper J, Isbrandt D (2002) Activation of GABA(A) receptors by guanidinoacetate: a novel pathophysiological mechanism. Neurobiol Dis 11:298–307CrossRef
Metadata
Title
Dietary guanidinoacetic acid does not accumulate in the brain of healthy men
Authors
Sergej M. Ostojic
Jelena Ostojic
Publication date
01-12-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nutrition / Issue 8/2018
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-017-1600-2

Other articles of this Issue 8/2018

European Journal of Nutrition 8/2018 Go to the issue